Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Unity Biotechnology Inc. shares valued at $6,579 were sold by Ghosh Anirvan on Sep 14. At $0.48 per share, Ghosh Anirvan sold 13,706 shares. The insider’s holdings dropped to 983,210 shares worth approximately $0.42 million following the completion of this transaction.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Also, Dananberg Jamie sold 10,923 shares, netting a total of over 5,243 in proceeds. Following the sale of shares at $0.48 each, the insider now holds 661,213 shares.
Before that, Ghosh Anirvan had sold 10,446 shares from its account. In a trade valued at $6,999, the Chief Executive Officer traded Unity Biotechnology Inc. shares for $0.67 each. Upon closing the transaction, the insider’s holdings decreased to 10,446 shares, worth approximately $0.43 million.
As published in a research note from ROTH Capital on January 04, 2022, Unity Biotechnology Inc. [UBX] has been rated up from a Neutral to a Buy. Analysts at Mizuho upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in early November. As of June 28, 2021, Citigroup has increased its “Sell” rating to a “Buy” for UBX. Earlier on June 07, 2021, H.C. Wainwright initiated its rating. Their recommendation was “a Buy” for UBX stock.
Analyzing UBX’s Price Performance
On Wednesday, Unity Biotechnology Inc. [NASDAQ: UBX] plunged -5.00% to $0.43. The stock’s lowest price that day was $0.42, but it reached a high of $0.44 in the same session. During the last five days, there has been a drop of approximately -10.44%. Over the course of the year, Unity Biotechnology Inc. shares have dropped approximately -70.86%. Shares of the company reached a 52-week high of $1.9110 on 01/04/22 and a 52-week low of $0.4200 on 09/21/22. A 50-day SMA is recorded $0.6650, while a 200-day SMA reached $0.9457. Nevertheless, trading volume fell to 1.29 million shares from 0.88 million shares the previous day.
Support And Resistance Levels for Unity Biotechnology Inc. (UBX)
According to the 24-hour chart, there is a support level at 0.4169, which, if violated, would cause prices to drop to 0.4085. In the upper region, resistance lies at 0.4369. The next price resistance is at 0.4485. RSI (Relative Strength Index) is 36.68 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0270, which suggests the price will decrease in the coming days. Percent R is at 95.08%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
Is Unity Biotechnology Inc. subject to short interest?
Stocks of Unity Biotechnology Inc. saw a sharp steep in short interest on Jul 14, 2022 dropping by -0.17 million shares to 0.22 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 0.39 million shares. A decline of -76.33% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 0.5 of the overall float, the days-to-cover ratio (short ratio) decline to 0.5.
Which companies own the most shares of Unity Biotechnology Inc. (UBX)?
According to The Vanguard Group, Inc. filings, the company currently owns 1,268,108 shares, which is about 0.95% of the total UBX shares outstanding. The investor’s shares have appreciated by 156,478 from its previous 13-F filing of 1111630.0 shares. With the completion of the buy transaction, Renaissance Technologies LLC’s stake is now worth $445,339. Fidelity Management & Research Co reduced a -56.37% interest valued at $0.43 million while GSA Capital Partners LLP sold a -84,265 stake. A total of -43,630 shares of Unity Biotechnology Inc. were sold by Marshall Wace LLP during the quarter, and 0 by Baillie Gifford & Co. In its current portfolio, BlackRock Fund Advisors holds 568,538 shares valued at $0.26 million.